We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 1-10 of 36

Recent developments in biosimilars: Canada, EU, France and the U.S.
  • Norton Rose Fulbright Canada LLP
  • USA, Canada, European Union, France
  • January 29 2014

There have been a number of developments in biosimilars of late, including regulatory approvals in Canada issued on January 15, 2014 for two

Canada: transparency of dealings between pharmaceutical companies and healthcare professionals
  • Norton Rose Fulbright LLP
  • Canada, European Union, France, USA
  • October 30 2013

Several countries have recently introduced legislation andor industry codes promoting the transparency of payments by pharmaceutical manufacturers

Canada and the US move to detect and further prevent foodborne illnesses
  • Norton Rose Fulbright Canada LLP
  • Canada, USA
  • September 18 2009

The Canadian government recently announced an injection of $75 million into Canada's food safety system to further improve Canada's ability to prevent, detect and respond to future foodborne illness outbreaks

Pharma in brief- Canada: Ontario Court of Appeal upholds injunction preventing an online generic drug retailer from selling drugs sourced in India to customers in the United States from an Ontario call centre
  • Norton Rose Fulbright Canada LLP
  • Canada, India, USA
  • July 26 2013

Global Pharmacy Canada (“GPC”) is an online prescription drug retailer that sells drugs sourced in India to customers in the United States. GPC is a

Huw Evans
  • Norton Rose Fulbright LLP

Demian Barbas
  • Norton Rose Fulbright LLP

Christopher N. Hunter
  • Norton Rose Fulbright LLP

Cori Annapolen Goldberg
  • Norton Rose Fulbright LLP

Daniel Daniele
  • Norton Rose Fulbright LLP

Jenna Anne de Jong
  • Norton Rose Fulbright LLP